Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 5Phase 1/2 2Phase 3 1

Status

Completed 5

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5CNS 5

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 9Leukemia 7Leukemia, Myeloid, Acute 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Glioma 4Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Philadelphia Chromosome 3Pancreatic Neoplasms 3Oligodendroglioma 3Myeloproliferative Disorders 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Astrocytoma 3Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Temozolomide 38Radiotherapy 21Radiosurgery 21Irinotecan 11Cyclophosphamide 11Radiation 10Magnetic Resonance Spectroscopy 10Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9Filgrastim 8Carboplatin 8pembrolizumab 7Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5cediranib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Imatinib Mesylate × Clear all
NCT00401024 2018-06-28

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
3 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00354068 2013-03-28

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Duke University

Phase 1 Completed
65 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00613132 2013-02-20

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Duke University

Phase 1 Completed
78 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00613054 2012-12-05

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Duke University

Phase 1 Completed
27 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡